• 1. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 2. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 3. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 4. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzofurans Dibenzofurans

Recent Advances in the Study of (2-Dibenzob,dfuran-2-ylethyl)amine (CAS: 108123-77-9) in Chemical Biology and Pharmaceutical Research

The compound (2-Dibenzob,dfuran-2-ylethyl)amine, with the CAS number 108123-77-9, has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique dibenzofuran scaffold, has shown promising potential in various therapeutic applications, including neuropharmacology and oncology. Recent studies have focused on elucidating its mechanism of action, optimizing its synthetic pathways, and exploring its biological activities. This research brief aims to provide a comprehensive overview of the latest findings related to this compound, highlighting its significance in current scientific endeavors.

One of the key areas of interest in recent research has been the synthesis and structural modification of (2-Dibenzob,dfuran-2-ylethyl)amine. A study published in the Journal of Medicinal Chemistry (2023) detailed an efficient synthetic route for this compound, emphasizing its scalability and purity. The researchers employed a multi-step process involving palladium-catalyzed cross-coupling reactions, which yielded the target molecule with high enantiomeric purity. This advancement is particularly noteworthy as it addresses previous challenges related to the compound's synthesis, paving the way for its broader application in drug development.

In addition to its synthetic improvements, (2-Dibenzob,dfuran-2-ylethyl)amine has been investigated for its neuropharmacological properties. A recent preclinical study demonstrated its potent affinity for serotonin receptors, specifically the 5-HT2A subtype. This finding suggests potential applications in the treatment of neuropsychiatric disorders such as depression and anxiety. The study, conducted on rodent models, reported significant behavioral improvements without the adverse effects commonly associated with traditional serotonergic agents. These results underscore the compound's potential as a novel therapeutic agent with a favorable safety profile.

Another promising avenue of research involves the compound's antitumor activity. A 2024 study published in Cancer Research explored the effects of (2-Dibenzob,dfuran-2-ylethyl)amine on various cancer cell lines, including glioblastoma and breast cancer. The compound exhibited selective cytotoxicity against tumor cells while sparing normal cells, a property attributed to its ability to induce apoptosis via the mitochondrial pathway. Furthermore, the study identified a synergistic effect when the compound was combined with conventional chemotherapeutic agents, suggesting its potential as an adjunct therapy in oncology.

Despite these encouraging findings, challenges remain in the clinical translation of (2-Dibenzob,dfuran-2-ylethyl)amine. Pharmacokinetic studies have revealed limitations in its oral bioavailability, prompting ongoing research into formulation strategies such as nanoparticle encapsulation. Additionally, further investigations are needed to fully elucidate its off-target effects and long-term safety. Nevertheless, the compound's unique chemical structure and multifaceted biological activities position it as a valuable candidate for future drug development efforts.

In conclusion, recent research on (2-Dibenzob,dfuran-2-ylethyl)amine (CAS: 108123-77-9) has highlighted its potential in neuropharmacology and oncology, driven by advancements in synthesis and a deeper understanding of its biological mechanisms. While challenges persist, the compound's promising preclinical results warrant continued exploration. Future studies should focus on optimizing its pharmacokinetic properties and conducting rigorous clinical trials to validate its therapeutic efficacy. This brief underscores the importance of interdisciplinary collaboration in advancing the development of novel pharmaceutical agents like (2-Dibenzob,dfuran-2-ylethyl)amine.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)